Long-term outcomes - Mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases

Nephrology Dialysis Transplantation

Volumn 25, Issue 12, 2010, Pages 3939-3948

  Cortés Hernández, Josefina ^a   Torres Salido, María Teresa ^a   Medrano, Alfonso Segarra ^a   Tarrés, Miquel Vilardell ^a   Ordi Ros, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

lupus nephritis; mycophenolate mofetil; systemic lupus erythematosus; tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADD ON THERAPY; ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAND TREMOR; HERPES ZOSTER; HUMAN; HYPOALBUMINEMIA; KIDNEY BIOPSY; LEUKOPENIA; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEINURIA; RELAPSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TACROLIMUS; TREATMENT OUTCOME;

EID: 78649517139     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq322     Document Type: Article

References (40)

1. Rosner S, Ginzler EM, Diamond HS et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982; 25: 612-617
2. Flanc RS, Roberts MA, Strippoli GF et al. Treatment of diffuse pro-liferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208
3. Donadio JV Jr, Holley KE, Ferguson RH et al. Treatment of diffuse proliferative lupus nephritis with prednisone and combined predni-sone and cyclophosphamide. N Engl J Med 1978; 299: 1151-1155
4. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162
5. Walsh M, James M, Jayne D et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2: 968-975
6. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
7. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10: 504-510
8. Flores-Suárez LF. Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofetil. Arch Med Res 2006; 37: 68-73
9. Zhu B, Chen N, Lin Y et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22: 1933-1942
10. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for pro-liferative lupus nephritis. N Engl J Med 2004; 350: 971-980
11. Chan TM, Tse KC, Tang CS et al. Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084
12. Lu F, Tu Y, Peng X et al. On behalf of the MMF in Induction Therapy for Active Lupus Nephritis in Mainland China Study Group. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 2008; 17: 622-629
13. Anselm M, Cheak AAC, Tan JYS et al. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology 2009; 48: 944-952
14. Appel GB, Contreras G, Dooley MA et al. Aspreva Lupus Management Study Group. J Am Soc Nephrol 2009; 20: 1103-1112
15. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118
16. Badid C, Vincent M, McGregor B et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61
17. Valeri A, Radhakrishnan J, Estes D et al. Intravenous pulse cyclo-phosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994; 42: 71-78
18. Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum 2006; 36: 71-81
19. Ferrario L, Bellone M, Bozzolo E et al. Remission from lupus nephritis resistant to cyclophosphamide alters additional treatment with cy-closporin A. Rheumatology (Oxford) 2000; 39: 218-220
20. Tam LS, Li EK, Leung CB et al. Long-term treatment of lupus nephritis with cyclosporine. A QJM 1998; 91: 573-580
21. Moroni G, Doria A, MoscaM et al. Arandomized pilot trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006; 1: 925-932
22. Mok CC, Tong KH, To CH et al. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005; 68: 813-817
23. Austin HA 3rd, Illei GG, Braun MJ et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20: 901-911
24. Bao H, Liu Z-H, Xie H-L et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008; 19: 2001-2010
25. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
26. Churg J, Bernstein J, Glassock RJ (eds). Renal diseases. Classification and Atlas of Glomerular Diseases. New York: Igaku-Shoin, 1995; 151-156
27. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250
28. Austin HA 3rd, Muenz LR, Joyce KM et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75: 382-391
29. Gordon C, Jayne D, Pusey C et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18: 257-263
30. Bertsias G, Boumpas DT. Update on the management of lupus nephritis: let the treatment fit the patient. Nat Clin Pract Rheumatol 2008; 4: 464-472
31. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291
32. Cortés-Hernández J, Ordi-Ros J, Labrador M et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 287-296
33. Pisoni CN, Sanchez FJ, Karim Y et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047-1052
34. Mak SK, Lo KY, Lo MW et al. Efficacy of enteric-coated mycophe-nolate sodium in patients with active lupus nephritis. Nephrology (Carlton) 2008; 13: 331-336
35. Austin HA 3rd, Boumpas DT, Vaughan EM et al. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995; 10: 1620-1628
36. Yoo CW, Kim M-K, Lee HS. Predictors of renal outcome in diffuse proliferative lupus nephropathy: data from repeat renal biopsy. Nephrol Dial Transplant 2000; 15: 1604-1608
37. Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-3940
38. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse im-munosuppressive therapy: long-term follow up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46: 995-1002
39. Moroni G, Quaglini S, Maccario M et al. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047-2053
40. Szeto CC, Kwan BC, Lai FM et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology 2008; 47: 1678-1681